EGFR and non-small cell lung carcinoma: The results of TROPION-PanTumor01 justified the conduction of the TROPION-Lung05 phase II trial dedicated to NSCLC patients with actionable genetic alterations (56.9% harbored EGFR mutations) with progression after at least one line of targeted therapy or platinum-based chemotherapy.